股東特別大會通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SINOPHARM GROUP CO. LTD. * 01099 茲通告國藥控股股份有限公司（「本公司」）謹訂於2025年12月19日（星期五）上午九時半假 座中華人民共和國（「中國」）上海市黃浦區龍華東路385號國藥控股大廈1401會議室舉行股 東特別大會（「股東特別大會」），藉以考慮並酌情通過以下決議案： 普通決議案 * 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港 公司。 - 1 - 1. 審議及酌情批准委任晉斌先生為第六屆董事會非執行董事，並授權董事會釐定其酬 金及授權本公司董事長或任何一位執行董事與其簽訂服務合約或該等其他文件或補 充協議或契據。 2. 審議及酌情批准委任楊秉華先生為第六屆董事會執行董事，並授權董事會釐定其酬 金及授權本公司董事長或任何一位執行董事與其簽訂服務合約或該等其他文件或補 充協議或契據。 ...

此乃要件 請即處理 閣下對本通函如有任何疑問，應徵詢獨立專業意見。 閣下如已出售或轉讓名下所有國藥控股股份有限公司H股，應立即將本通函連同隨附的代理人 委任表格送交買方或承讓人或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買方 或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SINOPHARM GROUP CO. LTD. * 01099 (1)建議委任非執行董事； (2)建議委任執行董事；及 (3)股東特別大會通告 董事會函件載於本通函第3-8頁。本公司謹訂於2025年12月19日（星期五）上午九時半假座中國 上海市黃浦區龍華東路385號國藥控股大廈1401會議室舉行股東特別大會，召開股東特別大會 的通告將連同本通函按股東就收取公司通訊已作出選擇的方式寄發予股東。 如股東擬委任代理人出席股東特別大會，務請按照適用代理人委任表格印列之指示填妥及交回 代理人委任表格。本代理人委任表格必須由 閣下或 閣下以書面正式授權的人士簽署，如屬 ...

格隆汇12月3日｜有投资者在互动平台向禾元生物提问：公司和国药控股的合作中，国药控股是作为合 同指定区域的独家代理，负责指定区域的药品销售，还是只是负责指定区域的药品配送，药品的销售推 广是由公司自己负责推销？这和贝达药业的合作模式是一样的吗？ 禾元生物回复称，公司已与国药控股、贝达药业等多家药品经销商签订经销协议，完成了全国30余个省 市区域的销售网络布局。国药控股是公司在特定区域的商业化合作伙伴。双方正在积极开展产品的学术 推广、市场拓展及渠道建设等相关工作，共同推动产品的市场覆盖和临床应用。 ...

Group 1 - The core viewpoint of the article highlights the collaboration between He Yuan Bio and China National Pharmaceutical Group (Sinopharm) as a commercial partner in specific regions, focusing on product promotion and market expansion [1] - He Yuan Bio has established a sales network across more than 30 provinces and cities in China through agreements with multiple distributors, including Sinopharm and Betta Pharmaceuticals [1] - The company is actively engaged in academic promotion, market development, and channel construction with Sinopharm to enhance product market coverage and clinical application [1]

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (HKD) closed at 4433.77 points, down 0.69%, with a trading volume of 6.716 billion HKD and a turnover rate of 0.73% [1] - Among the index constituents, 18 stocks rose while 39 stocks fell, with Global Medical leading the gainers at 3.66% and Health Road leading the decliners at 6.35% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (14.56% weight, latest price 200.62, market cap 243.24 billion) [1] - Yier Eye Hospital (11.62% weight, latest price 11.50, market cap 107.24 billion) [1] - Lejin Medical (4.85% weight, latest price 15.74, market cap 29.01 billion) [1] - Aimeike (4.80% weight, latest price 145.06, market cap 43.89 billion) [1] - Yuyue Medical (4.66% weight, latest price 35.82, market cap 35.91 billion) [1] - Yingke Medical (3.64% weight, latest price 42.40, market cap 27.78 billion) [1] - Furuide (3.59% weight, latest price 67.36, market cap 17.85 billion) [1] - Meinian Health (3.58% weight, latest price 5.21, market cap 20.39 billion) [1] - Sinopharm (3.35% weight, latest price 18.63, market cap 58.14 billion) [1] - Ping An Good Doctor (2.63% weight, latest price 13.39, market cap 28.93 billion) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 83.77 million HKD, while retail investors saw a net inflow of 61.08 million HKD [1] - Specific stock capital flows include: - Mindray Medical: main fund net inflow of 37.11 million, retail net outflow of 4.23 million [2] - Yuyue Medical: main fund net inflow of 3.70 million, retail net inflow of 4.71 million [2] - Over the past 10 days, one stock was newly added to the index [2]

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

Core Points - Zhao Bingxiang has resigned from his position as Chairman of Sinopharm Holdings after 14 months due to work arrangement reasons [2][3] - Jin Bin, a veteran from the Sinopharm system, will succeed Zhao as Chairman, with Li Ying also proposed as a non-executive director [3] - Sinopharm Holdings is a subsidiary of China National Pharmaceutical Group and a leading player in China's pharmaceutical distribution industry [3] Financial Performance - In the first half of 2024, Sinopharm Holdings reported total revenue of 294.73 billion yuan, a year-on-year decrease of 2.07% [4] - The medical device distribution and retail businesses experienced revenue declines of 7.08% and 6.43%, respectively, while the pharmaceutical distribution business saw a slight revenue increase of 0.47% [4] - The company's net profit attributable to shareholders fell by 9.76% to 3.704 billion yuan due to declining revenue and lower gross margins [4] Strategic Initiatives - Zhao emphasized the importance of innovation and service transformation in the company's annual report, aiming to enhance profitability and value [4] - The company is focusing on strengthening its service-oriented business models, including marketing services, third-party logistics, and private label manufacturing [4] - In the first half of 2025, the company continued to face revenue and profit declines, with a reported revenue of 286 billion yuan, down 2.95% year-on-year [5]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Policy Developments - The National Healthcare Security Administration exposed a healthcare fraud industry chain in Shanghai, leading to the prosecution of an individual for fraud, resulting in significant losses to the national healthcare fund [1] - The crackdown on healthcare fraud has become more systematic and normalized in recent years, highlighting the importance of protecting the healthcare fund [1] Drug and Device Approvals - Anglicon received a drug registration certificate for Ertugliflozin Metformin Extended-Release Tablets, aimed at improving blood sugar control in adults with type 2 diabetes [2] - Betta Pharmaceuticals announced that its application for the marketing authorization of Ensartinib Capsules for treating ALK-positive non-small cell lung cancer has been accepted by the European Medicines Agency [3] - Innovent Biologics received approval for its IL-23p19 monoclonal antibody for the treatment of moderate to severe plaque psoriasis in adults [4] - Warner Pharmaceuticals obtained a drug registration certificate for Formoterol Fumarate Inhalation Solution, intended for the maintenance treatment of COPD [5] - Shanghai Pharmaceuticals announced that its Tramadol Hydrochloride Injection passed the consistency evaluation for generic drugs, which may enhance its market competitiveness [6] Major Industry Events - Biontech received a milestone payment of $250 million from Bristol-Myers Squibb related to the Iza-bren project, with potential for additional payments based on future milestones [7] - Jining Pharmaceutical plans to invest 893 million yuan in a hospital expansion project to meet the growing health demands in the region [8] - Maiwei Biotech completed Phase IIa clinical trials for its innovative drug 9MW1911 in COPD patients, showing significant reductions in acute exacerbation rates [9] Shareholder Actions - Sanofi Biotech announced plans for shareholders to reduce their holdings by a total of 0.0240% of shares due to personal financial needs [10] Management Changes - Sinopharm Holdings announced management changes, including the resignation of several executives and the appointment of new leadership, which will take effect upon shareholder approval [11]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the resignation of key board members and the appointment of new directors, indicating a significant leadership change within the company [1] Group 1: Resignations - Mr. Zhao Bingxiang has resigned from multiple positions including non-executive director, chairman of the board, and various committee roles effective from the date of appointment of his successors at the shareholders' meeting [1] - Ms. Feng Rongli has also resigned from her roles as non-executive director and committee member, with her resignation effective upon the appointment of her successor [1] Group 2: Appointments - The board has proposed the appointment of Mr. Jin Bin and Ms. Li Ying as non-executive directors [1] - Mr. Jin has been elected as chairman and authorized representative, pending shareholder approval for his non-executive director appointment [1] - Mr. Jin will also serve as the chairman of the nomination committee, strategic and investment committee, and as a member of the legal compliance and environmental, social, and governance committee, subject to shareholder approval [1]